- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a product name.
BioCentury | Apr 28, 2025
Deals
Eight-year-run for Pfizer spinout Springworks culminates in Merck KGaA buyout
German pharma adds drugs for rare tumors, expands U.S. footprint via $3.9B acquisition
BioCentury | Oct 15, 2024
Product Development
A new chapter for progressive MS?
NIH’s Reich on recent data that could shape drug development’s future for progressive multiple sclerosis, and neurodegeneration broadly
BioCentury | Jan 7, 2023
Discovery & Translation
Autocrine signaling targets for fibrosis in NASH; plus a blood-based biomarker for Alzheimer’s and more
BioCentury’s roundup of translational news
BioCentury | Oct 21, 2022
Deals
Biogen’s acquisition conundrum
How Biogen could acquire its way into being a near-term growth company
BioCentury | Nov 20, 2021
Product Development
Is it time for Biogen to re-diversify?
Sandrock’s departure creates opportunity for his successor to reconsider neurology focus
BioCentury | Oct 15, 2021
Management Tracks
Malek joins NIBR as head of oncology disease area
Plus: Translate Bio vet Smith joins CRISPR as CFO and updates from Travere, Kojin, AMO, Poseida, Synairgen and more
BioCentury | Aug 21, 2021
Targets & Mechanisms
Next-generation multiple sclerosis therapies look beyond B cells
Early-stage approaches aim for more precise immune suppression, remyelination
BioCentury | Jun 16, 2021
Regulation
FDA’s Woodcock reflects on aducanumab, drug approval standards, the future of clinical trials
Acting FDA Commissioner Janet Woodcock reflects on the past and future of drug development
BioCentury | Apr 2, 2020
Product Development
COVID-19 roundup: EMA seeks to rein in chloroquine use; plus cash for CEPI, WHO’s SOLIDARITY grows, CytoDyn, EUSA, Chembio, PCR Biosystems and more
BioCentury is providing this story for free given the urgent need for information about the COVID-19 crisis. For more analysis, sign up for our daily email.
BioCentury | Mar 28, 2020
Product Development
COVID-19 roundup: FDA approves Abbott’s 5-minute test; plus Trump signs stimulus bill, WHO readies master protocol, CytoDyn mAb data and more
BioCentury is providing this story for free given the urgent need for information about the COVID-19 crisis. For more analysis, sign up for our daily email.
Items per page:
1 - 10 of 752